Effects of selective vs. nonselective cyclooxygenase inhibition on dynamic renal potassium excretion: A randomized trial

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 2, 2008, Pages 208-211

  Preston, R A ^a   Afshartous, D ^a   Alonso, A B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FUROSEMIDE; IBUPROFEN; INDOMETACIN; NAPROXEN; PLACEBO; POTASSIUM; POTASSIUM CHLORIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EXCRETION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FRACTIONAL POTASSIUM EXCRETION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HYPERKALEMIA; LOADING DRUG DOSE; MIXED EFFECTS MODEL; POTASSIUM BLOOD LEVEL; POTASSIUM HANDLING CURVE; POTASSIUM TRANSPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL MODEL; TRANSPORT KINETICS; URINARY EXCRETION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; IBUPROFEN; KIDNEY; MALE; MIDDLE AGED; MODELS, STATISTICAL; POTASSIUM; PYRAZOLES; RESEARCH DESIGN; SULFONAMIDES; TIME FACTORS;

EID: 49149102940     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.16     Document Type: Article

References (29)

1. Harris, R.C. COX-2 and the kidney. J. Cardiovasc. Pharmacol. 47(suppl. 1), S37-S42 (2006).
2. Perazella, M.A. Drug-induced hyperkalemia: old culprits and new offenders. Am. J. Med. 109, 307-314 (2000).
3. Harris, R.C., Zhang, M.Z. & Cheng, H.F. Cyclooxygenase-2 and the renal renin-angiotensin system. Acta. Physiol. Scand. 181, 543-547 (2004).
4. Cheng, H.F. & Harris, R.C. Cyclooxygenases, the kidney, and hypertension. Hypertension 43, 525-530 (2004).
5. Schlondorrf, D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 44, 643-653 (1993).
6. Hay, E., Derazon, H., Bukish, N., Katz, L., Kruglyakov, I. & Armoni, M. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor, and potassium rich diet. J. Emerg. Med. 22, 349-353 (2002).
7. Lam, Q. & Scneider, H.-G. Hyperkalemia with cyclooxygenase-2 inhibition and hypoaldosteronism. Internal Med. J. 35, 1 (2005).
8. Braden, G.L., O'Shea, M.H., Mulhern, J.G. & Germain, M.J. Acute renal failure and hyperkalemia associated with cyclooxygenase-2 inhibitors. Nephrol. Dial. Transplant. 19, 1149-1153 (2004).
9. Swan, S.K. et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann. Intern. Med. 133, 1-9 (2000).
10. Rossat, J., Maillard, M., Nussberger, J., Brunner, H.R. & Burnier, M. Renal effects of selective cyclooxygenase-2 inhibition innormotensive salt-depleted subjects. Clin. Pharmacol. Ther. 66, 76-84 (1999).
11. Stichtenoth, D.O., Merhauer, V., Tsikas, D., Gutzki, F.M. & Frolich, J.C. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int. 68, 2197-2207 (2005).
12. Whelton, A. et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch. Intern. Med. 160, 1465-1470 (2000).
13. Laird, N. & Ware, J.H. Random effects models for longitudinal data Biometrics 38, 963-974 (1982).
14. Dartois, C. et al. Overview of model building strategies in population PK/PD analyses. Br. J. Clin. Pharmacol. 64, 603-612 (2007).
15. Gupta, S., Juif, J., Kolz, K. & Cutler, D. Does selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukemia. Br. J. Clin. Pharmacol. 63, 292-299 (2007).
16. Gonick, H.C., Kleeman, C.R., Rubini, M.E. & Maxwell, M.H. Functional impairment in chronic renal disease: III, studies of potassium excretion. Am. J. Med. Sci. 261, 281-290 (1971).
17. Preston, R.A., Baltodano, N.M., Alonso, A. & Epstein, M. Comparative effects on renal potassium excretion of candesartan versus lisinopril in hypertensive patients with type II diabetes mellitus. J. Clin. Pharmacol. 42, 754-761 (2002).
18. Oster, J.R., Lanier, D.C. & Vaamonde, C.A. Renal response to potassium loading in sickle cell trait. Arch. Intern. Med. 140, 534-536 (1980).
19. Perez, G.O., Pelleya, R., Oster, J.R., Kem, D.C. & Vaamonde, C.A. Blunted kaliuresis after an acute potassium load in patients with chronic renal failure. Kidney Int. 24, 656-662 (1983).
20. Perez, G.O., Lespier, L., Knowles, R., Oster, J.R. & Vaamonde, C.A. Potassium homeostasis in chronic diabetes mellitus. Arch. Intern. Med. 137, 1018-1022 (1977).
21. Efron, B. & Tibshirani, B. An Introduction to the Bootstrap (Chapman & Hall, New York, 1993).
22. Holm, S. A simple sequentially rejective multiple test procedure. Scand. J. Statist. 6, 65-70 (1979).
23. Afshartous, D. & Wolf, M. Avoiding data snooping in mixed effects and multilevel models. J. R. Stat. Soc. Ser. A 170, 1035-1059 (2007).
24. Verbeke, G. & Molenberghs, G. Linear Mixed Models for Longitudinal Data (Springer, New York, 2000).
25. Afshartous, D. & de Leeuw, J. A predictive density approach to predicting future observables in the multilevel model. J. Stat. Plan. Inference, 128, 149-164 (2005).
26. Afshartous, D. & de Leeuw, J. Prediction in multilevel models. J. Educ. Behav. Stat. 30, 109-139 (2005).
27. Afshartous, D. & de Leeuw, J. A decomposition of prediction error for the multilevel model. Commun. Stat. Simul .Comput. 34, 909-928 (2005).
28. R Project. R - Version 2.5.1. Vienna: R Project. 〈http://www.r- project.org〉 (2007).
29. Pinheiro, J.C. & Bates, D.M. Mixed-Effects Models in S and S-PLUS (Springer, New York, 2000).